Pereira Arias J G, Maraña Fernandez M, Escobal Tamayo V, Ibarluzea González J G, Bernuy Malfaz C
Servicio de Urología, Hospital de Galdakao, Vizcaya.
Actas Urol Esp. 1995 May;19(5):401-6.
The introduction of self-expandable urethral endoprostheses for the management of relapsing urethral stenosis has required the development of a minimally invasive therapeutical approach of widespread acceptance by the urological community. The reason for its success is the simplicity of implantation and the low rate of complications up to date. This paper reports on a patient carrying a ¿Urolume¿ urethral endoprosthesis for a relapsing bulbar urethral stenosis, which two years after implantation presents re-stenosis secondary to endoluminal inflammatory tissue growth. After two failure endoscopic resections, endoscopic removal of the prosthesis was required. Currently the patient carries a ¿Urocoil¿ spiral endoprosthesis to avoid tissular reaction. The therapeutical aspects found in the literature are reviewed, emphasizing the need of follow-up to detect complications, to improve indications and to select those patients that may be candidates for this treatment.
自膨式尿道内支架用于复发性尿道狭窄的治疗，这需要开发一种微创治疗方法，以得到泌尿外科界的广泛认可。其成功的原因在于植入操作简单，且迄今为止并发症发生率较低。本文报道了一名患有复发性球部尿道狭窄并植入“Urolume”尿道内支架的患者，植入两年后因腔内炎性组织生长出现再狭窄。在两次内镜切除失败后，需要内镜下取出支架。目前该患者植入了“Urocoil”螺旋内支架以避免组织反应。本文回顾了文献中发现的治疗方面的问题，强调需要进行随访以检测并发症、改善适应症并选择可能适合这种治疗的患者。
